The United States, a hotbed of medical innovation, stands at a crossroads. Despite our vast potential to tackle devastating diseases, I believe a fundamental flaw in our approach to health innovation leaves a wealth of promising breakthroughs yet to be explored.
For the sake of public health, the status quo must change.
SQUANDERING THE POTENTIAL FOR NOVEL INNOVATIONS
Surprisingly, major health corporations allocate a minor portion of their revenue to research and development, favoring sales and marketing instead. Emerging biopharma companies have become the backbone of innovation, accounting for two-thirds of the molecules in the R&D pipeline in 2022. This shift from a third in 2001, as reported by IQVIA, signals a growing reliance on smaller entities for breakthroughs.
When these smaller entities create promising breakthroughs, more prominent companies acquire them quickly. However, large companies prefer to acquire innovations that address high-profile and widespread ailments targeting higher profit returns. While these treatments are essential, rarer diseases often get pushed to the wayside. A “rare disease” is classified by the National Institute of Health as having less than 200,000 cases per year, a significantly smaller market to tap.
However, most smaller companies with promising ideas never reach the acquisition phase. That’s not because their innovations aren’t worthwhile. The journey from concept to market is fraught with challenges—a single mistake, and these innovations will never see the light of day. Importantly, companies focused on less common diseases have an even higher failure rate and are often overlooked by investors.
The health market incentivizes a repetitive cycle of developing treatments for the same conditions, squandering the potential of novel innovations. This approach is a disservice to public health and demands a fundamental overhaul. Roughly 30 million Americans—or one in ten people—have a rare disease. However, 95% of these diseases have no treatment.
The U.S. has taken some steps to address this stalled innovation. For example, back in 1983, Congress passed the Orphan Drug Act, which financially incentivizes companies to create treatments for rare diseases. That law caused treatments for little-known conditions to skyrocket.
WHERE CAN WE GO FROM HERE?
Now, four decades later, I believe we need to take rare disease development to the next level. For example, companies should receive bonus incentives for research into diseases that are considered “ultra-rare,” meaning conditions that afflict less than 10,000 Americans. These conditions often go neglected because companies don’t think they can generate enough revenue with such a small patient pool.
There’s also legislation in Congress that would unlock care options for patients with rare diseases. In late October, a bipartisan group of House Representatives introduced a bill that would give Medicare and Medicaid more flexibility to consider therapies initially produced to treat one specific disease to treat other conditions and rare diseases. Such legislation would not only improve access to a wider variety of treatments but could also spur more research into how existing drugs could help patients with rare diseases.
Additionally, since smaller companies are leading true health innovation, our government should shore up resources for these entities to succeed. For example, there could be more grants for smaller companies with promising innovations but needing more financial or other support to keep up their work. For example, if a company has a hopeful clinical trial that goes slightly awry, it should be able to plead its case and access funding for another round.
The government could also offer incentives for smaller companies to remain independent from big health companies. If smaller companies could access grant funding to market and sell their drugs, they could continue to put their resources toward what they do best: innovation.
Furthermore, regardless of their size, pharmaceutical companies should explore avenues for greater engagement of stakeholders in the innovation process. By incorporating input from a broad spectrum of individuals rather than relying on decisions made by a select few, we can aspire to create a world that genuinely betters patients’ lives.
The potential to cure diseases that affect millions worldwide is within our grasp. We cannot allow outdated systems to impede this progress. It’s time for a systemic change in how we approach health innovation—for the benefit of all.
Amro Albanna is the Co-Founder, CEO and Chairman of Aditxt.